Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients
NCT03541863 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 131
Last updated 2019-02-15
Summary
What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China.
Conditions
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Biyun Wang, Professor · Fudan University
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-10-10
- Primary Completion
- 2018-12-15
- Completion
- 2018-12-20
Countries
- China
Study Locations
More Related Trials
-
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients
NCT01658033 ·Status: COMPLETED ·Phase: PHASE2
-
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
NCT04263298 ·Status: RECRUITING ·Phase: PHASE3
-
Treatment After Palbociclib-containing Regimens
NCT04517318 ·Status: COMPLETED
-
Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC
NCT05000736 ·Status: UNKNOWN
-
Faslodex Advanced Breast Cancer Local Chinese Study
NCT00327769 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
NCT06954961 ·Status: RECRUITING ·Phase: PHASE3
-
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
NCT06635447 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
NCT05186545 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
NCT05047848 ·Status: UNKNOWN ·Phase: NA
-
Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors
NCT05191914 ·Status: UNKNOWN ·Phase: PHASE4
-
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
NCT05433480 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
NCT06788197 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546 ·Status: RECRUITING ·Phase: PHASE2
-
Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy
NCT05806047 ·Status: UNKNOWN ·Phase: PHASE2
-
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
NCT02404051 ·Status: UNKNOWN ·Phase: PHASE3
-
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
NCT05075512 ·Status: RECRUITING ·Phase: PHASE2
-
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
NCT04001634 ·Status: COMPLETED
-
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
NCT06172322 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
NCT05504213 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
NCT03803761 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
NCT04796623 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer
NCT03939871 ·Status: UNKNOWN ·Phase: PHASE2